H. Lundbeck A/S (HLUN-A.CO)
- Previous Close
27.95 - Open
27.95 - Bid 28.15 x --
- Ask 28.20 x --
- Day's Range
27.95 - 28.30 - 52 Week Range
27.10 - 38.08 - Volume
53,240 - Avg. Volume
99,736 - Market Cap (intraday)
31.709B - Beta (5Y Monthly) --
- PE Ratio (TTM)
12.19 - EPS (TTM)
2.31 - Earnings Date May 15, 2024
- Forward Dividend & Yield 0.70 (2.49%)
- Ex-Dividend Date Mar 21, 2024
- 1y Target Est
--
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
www.lundbeck.com5,681
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: HLUN-A.CO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLUN-A.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLUN-A.CO
Valuation Measures
Market Cap
31.71B
Enterprise Value
30.85B
Trailing P/E
12.19
Forward P/E
10.24
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.40
Price/Book (mrq)
1.27
Enterprise Value/Revenue
1.55
Enterprise Value/EBITDA
6.10
Financial Highlights
Profitability and Income Statement
Profit Margin
11.50%
Return on Assets (ttm)
5.45%
Return on Equity (ttm)
10.69%
Revenue (ttm)
19.91B
Net Income Avi to Common (ttm)
2.29B
Diluted EPS (ttm)
2.31
Balance Sheet and Cash Flow
Total Cash (mrq)
5.01B
Total Debt/Equity (mrq)
18.83%
Levered Free Cash Flow (ttm)
2.94B
Company Insights: HLUN-A.CO
HLUN-A.CO does not have Company Insights